Médecine

Paramédical

Autres domaines


S'abonner

Subcutaneous efalizumab is not effective in the treatment of alopecia areata - 24/04/13

Doi : 10.1016/j.jaad.2007.10.645 
Vera H. Price, MD a, , Maria K. Hordinsky, MD b, Elise A. Olsen, MD c, Janet L. Roberts, MD d, Elaine C. Siegfried, MD e, Elyse S. Rafal, MD f, Neil J. Korman, MD, PhD g, Basel Altrabulsi, MD h, Hoi M. Leung, PhD i, Marvin R. Garovoy, MD j, Ivor Caro, MD k, David A. Whiting, MD l
a Department of Dermatology, University of California, San Francisco, California 
b University of Minnesota, Minneapolis, Minnesota 
c Duke University Medical Center, Durham, North Carolina 
d Northwest Dermatology and Research Center, Portland, Oregon 
e Central Dermatology, St. Louis, Missouri 
f DermResearchCenter of New York, Inc., Stony Brook, New York 
g University Hospitals/Case Medical Center, and the Murdough Family Center for Psoriasis, Cleveland, Ohio 
h Baylor University Medical Center, Dallas, Texas 
l Baylor Hair Research & Treatment Center, Dallas, Texas 
i Xoma, Berkeley, California 
j Arriva Pharmaceuticals, Alameda, California 
k Genentech, Inc., South San Francisco, California 

Reprint requests: Vera H. Price, MD, 1701 Divisadero Street, 3rd Floor, Box 0316, San Francisco, CA 94143-0316.

Abstract

Background

Alopecia areata (AA) is a T-cell–mediated autoimmune disease. Efalizumab is a T-cell–targeted therapy approved for the treatment of psoriasis.

Objective

To assess the efficacy and safety of efalizumab in the treatment of moderate-to-severe AA.

Methods

Sixty-two patients were enrolled into this phase II, placebo-controlled trial. The trial consisted of three 12-week periods—a double-blind treatment period, an open-label efalizumab treatment period, and a safety follow-up.

Results

There were no statistical differences between treatment groups in percent hair regrowth, quality-of-life measures, or changes in biologic markers of disease severity after 12 or 24 weeks. In both groups, there was an approximately 8% response rate for hair regrowth (at 12 weeks). Efalizumab was well tolerated.

Limitations

Numbers were too small for certain analyses.

Conclusion

A 3- to 6-month trial of efalizumab was not effective in promoting hair regrowth in this small cohort of patients with moderate-to-severe AA.

Le texte complet de cet article est disponible en PDF.

Plan


 Presented at the 2006 Society for Investigative Dermatology Annual Meeting, Philadelphia, PA, May 3-6, 2007.
 Supported by Genentech, Inc.
 Disclosures: Dr Price has received grant support and served as an investigator for Xoma and Genentech, Inc. Dr Hordinsky has received grant support and served as an investigator for Astellas and Genentech, Inc. Dr Roberts has received research support and is an investigator for Abbott. Dr Siegfried has been a paid investigator and received honoraria for Genentech, Inc. Dr Rafal has received grant support and served as an investigator for Serono International SA, Amgen, Biogen Idec, and Genentech, Inc. Drs Olsen and Altrabulsi have no conflicts of interest to disclose. Dr Korman has received grant support and honoraria and served as a speaker, consultant, and an advisory board member for Astellas and Novartis; he is an investigator for Novartis. Dr Leung is a stock shareholder and an employee of Xoma. Dr Garovoy is a stock shareholder and was an employee of Xoma, and has been a consultant of Genentech, Inc. Dr Caro is a stock shareholder and an employee of Genentech, Inc. Dr Whiting is an investigator for Xoma and Genentech, Inc.


© 2008  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 58 - N° 3

P. 395-402 - mars 2008 Retour au numéro
Article précédent Article précédent
  • Long-pulsed dye laser versus long-pulsed dye laser-assisted photodynamic therapy for acne vulgaris: A randomized controlled trial
  • Merete Hædersdal, Katrine Togsverd-Bo, Stine Regin Wiegell, Hans Christian Wulf
| Article suivant Article suivant
  • Anterior cervicoplasty: Neck rejuvenation using local anesthesia
  • John G. Hancox, Jeffrey S. Eaton

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.